New test could spot newborn blood disorder earlier
NCT ID NCT07371520
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether measuring bleeding between mother and baby can help diagnose hemolytic disease of the newborn (HDN), a condition where the mother's antibodies attack the baby's red blood cells. Researchers will test leftover blood samples from 100 pregnant women at high risk for HDN. The goal is to see if this bleeding detection method can accurately identify affected newborns, potentially leading to faster diagnosis and treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a new, non-invasive diagnostic tool for hemolytic disease of the newborn, enabling earlier treatment and better outcomes.
- What could go wrong
- This is an early observational study with only 100 participants, so results may not apply to all cases. The diagnostic method may not be accurate enough to replace current tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOLYTIC DISEASE OF THE NEWBORN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China